Pubblicazioni

Leader in Italia nella ricerca e nella
commercializzazione di kit diagnostici
per test farmacogenetici

1010, 2017

Elisabetta Tozzi et. al, The Headaches and Polymorphisms of the Methylenetetrahydrofolate Reductase

1809, 2017

Graziella Pinotti et al.,1335PEGFR T790M detection in TKI-naïve NSCLCs carrying sensitive EGFR mutations

1809, 2017

Elena Ongaro et al., 552PMutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study

809, 2017

Rossella Bruno et al., Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. Oncology Letters

2508, 2017

Deans ZC et al., Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey.

2408, 2017

Annamaria Ruzzo et al., Dihydropyrimidine dehydrogenase pharmaco- genetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. British Journal of Cancer

1008, 2017

Gianni Bussolati et al., Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. Plos One

1907, 2017

Marco Lucarelli et al., A New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology. The Journal of Molecular Diagnostics

1907, 2017

Francesca Galuppini et al., BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology

1807, 2017

Federico Pessina et al., Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. Future Medicine

807, 2017

Chiara Pesenti et al. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status

2806, 2017

Pierina Navarria et al., Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study

Precedente 232425 Successivo

Pubblicazioni

Leader in Italia nella ricerca e nella
commercializzazione di kit diagnostici
per test farmacogenetici

Cerca pubblicazione

Filtra per anno

Cerca per primo autore

Cerca per linea

Pubblicazioni

Leader in Italia nella ricerca e nella commercializzazione di kit diagnostici per test farmacogenetici

Cerca pubblicazione

Filtra per anno

Cerca per primo autore

Cerca per linea

Leader in Italia nella ricerca e nella
commercializzazione di kit diagnostici
per test farmacogenetici